Lucid Diagnostics
The company also recently published multiple new clinical validation studies to support its quest for reimbursement.
Lucid Diagnostics Raises $22M in Convertible Debt Refinancing
The cash raised brings the company’s total holdings to about $33 million, enough to see it through plans to gain reimbursement for its esophageal cancer test.
In Brief This Week: Quest Diagnostics, T2 Biosystems, Oncocyte, Myriad Genetics, More
News items for the week of Nov. 11, 2024
In Brief This Week: Labcorp, Quest Diagnostics, Abbott, Hologic, Agilent, More
News items for the week of Sept. 16, 2024.
Lucid Diagnostics Partners With Front Line Mobile to Promote Esophageal Cancer Test
Working with the first responder medical care provider, Lucid is planning high-volume testing events among firefighters and other frontline workers with elevated risk.